# Dapagliflozin Therapy In Cardiac Surgery

Study · id `cardio:ct-nct05621551` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05621551](<https://clinicaltrials.gov/study/NCT05621551>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05621551

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 178 participants.

## Technical summary

Registry record NCT05621551. Randomized; single masking; primary purpose treatment. Start 2022-11-11 (actual); primary completion 2024-06-01 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 178 participants (enrolled count; ClinicalTrials.gov record NCT05621551, source copy `cardio:ctgov-nct05621551-2025-07-15`, retrieved 2026-10-26)
- Started: 2022-11-11 (actual) (ClinicalTrials.gov record NCT05621551, source copy `cardio:ctgov-nct05621551-2025-07-15`, retrieved 2026-10-26)
- Primary completion: 2024-06-01 (actual) (ClinicalTrials.gov record NCT05621551, source copy `cardio:ctgov-nct05621551-2025-07-15`, retrieved 2026-10-26)
- Completion: 2025-06-01 (actual) (ClinicalTrials.gov record NCT05621551, source copy `cardio:ctgov-nct05621551-2025-07-15`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT05621551, source copy `cardio:ctgov-nct05621551-2025-07-15`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05621551-2025-07-15`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin Therapy In Cardiac Surgery
- Condition: Diabetes Mellitus, Type 2
- Condition: Cardiac Surgery
- Intervention (Drug): Dapagliflozin
- Lead sponsor: China National Center for Cardiovascular Diseases
- Lead sponsor class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: China National Center for Cardiovascular Diseases (`cardio:org-china-national-center-for-cardiovascular-diseases`)

## Provenance

Content hash: deb26f6ec2e09b4bb59a3f9d31a08e68d9d133ecb275bc039c3be5ad87f32e0c
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
